Urine cell-free DNA as a promising biomarker for early detection of non-small cell lung cancer

被引:16
|
作者
Ren, Sai [1 ]
Ren, Xiao-Dong [1 ]
Guo, Li-Fang [1 ]
Qu, Xue-Mei [1 ]
Shang, Mei-Yun [1 ]
Dai, Xiao-Tian [2 ]
Huang, Qing [1 ]
机构
[1] Army Med Univ, Dept Lab Med, Daping Hosp, Chongqing 400042, Peoples R China
[2] Army Med Univ, Dept Pulmonol, Southwest Hosp, Chongqing 400038, Peoples R China
关键词
DNA integrity; LINE1 repeat sequences; non-small-cell lung cancer; quantitative real-time PCR; urine cell-free DNA; FREE CIRCULATING DNA; PLASMA DNA; POTENTIAL MARKER; BLOOD-PLASMA; INTEGRITY; METHYLATION; PROGRESSION; PREDICTION; DIAGNOSIS; TUMOR;
D O I
10.1002/jcla.23321
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Background While blood-derived cell-free DNA has been shown to be a candidate biomarker able to provide diagnostic and prognostic insight in cancer patients, little is known regarding the potential application of urine cell-free DNA (ucfDNA) in diagnosis of cancer. Thus, the aim of this study was to investigate ucfDNA concentration and integrity index as potential biomarkers for early detection of non-small-cell lung cancer (NSCLC). Methods Urine samples were collected from 35 healthy controls and 55 NSCLC patients at various tumor node metastasis (TNM) stages. Two long interspersed nuclear element 1 (LINE1) fragments (LINE1-97 and 266 bp) were quantified via quantitative real-time PCR (qPCR). DNA integrity index was calculated as the ratio of LINE1-266/LINE-97. Results LINE1 fragments concentrations of ucfDNA (LINE1-97, 266 bp) were significantly higher in NSCLC patients with stage III/IV than in stage I/II and in healthy controls. The receiver operating characteristic (ROC) curves for discriminating patients with stage III/IV from healthy controls had areas under the curves (AUC) of 0.84 and 0.886, respectively. Moreover, ucfDNA integrity LINE1-266/97 was significantly higher in patients with stage III/IV than in stage I/II and in healthy controls. The AUC of ROC curve for discriminating patients with stage III/IV from healthy controls was 0.800. Furthermore, LINE1-266 fragment concentration was significantly higher in lymph node metastasis (LNM)-positive patients relative to LNM-negative patients. The ROC curve for discriminating LNM-positive from LNM-negative patients had an AUC of 0.822. Conclusion UcfDNA could serve as a promising biomarker for early detection of NSCLC.
引用
收藏
页数:7
相关论文
共 50 条
  • [21] Circulating Tumor Cell-Free DNA as Prognostic Biomarker in Non-Small Cell Lung Cancer Patients Undergoing Immunotherapy: The CORELAB Experience
    Gelmini, Stefania
    Calabri, Adele
    Mancini, Irene
    Comin, Camilla Eva
    Pasini, Valeria
    Banini, Marco
    Scotti, Vieri
    Pinzani, Pamela
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2025, 26 (02)
  • [22] 5-hydroxymethylcytosine in cell-free DNA as liquid biomarker for immune checkpoint inhibitor therapy in non-small cell lung cancer
    Ajmal, Zainub
    Shao, Jianming
    Olsen, Randall
    Kasparian, Saro
    He, Chuan
    Bernicker, Eric
    Li, Zejuan
    Zhang, Jun
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [23] Cell-Free DNA From Nontumor Tissue in Patients With Non-small Cell Lung Cancer Response
    Roosan, Moom R.
    Mambetsariev, Isa
    Salgia, Ravi
    CHEST, 2021, 160 (04) : E371 - E372
  • [24] Molecular profiling of cell-free DNA and RNA in the blood of patients with non-small cell lung cancer
    Reese, Jordan
    Jackson, Leisa
    Mellert, Hestia S.
    Pestano, Gary
    CANCER RESEARCH, 2019, 79 (13)
  • [25] A quantitative analysis of the potential biomarkers of non-small cell lung cancer by circulating cell-free DNA
    Wei, Lirong
    Wu, Wangxi
    Han, Liming
    Yu, Weimo
    Du, Yuzhen
    ONCOLOGY LETTERS, 2018, 16 (04) : 4353 - 4360
  • [26] Cell-Free Tumor DNA (ctDNA) Utility in Detection and Monitoring EGFR Mutations in Non-Small Cell Lung Cancer (NSCLC)
    Agulnik, J.
    Kasymjanova, G.
    Papadakis, A.
    Small, D.
    Sakr, L.
    Pepe, C.
    Wang, H.
    Cohen, V.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1035 - S1035
  • [27] Nestin servers as a promising prognostic biomarker in non-small cell lung cancer
    Liu, Fang
    Zhang, Yuan
    Lu, Ming
    Wang, Cong
    Li, Qingbao
    Gao, Yongsheng
    Mu, Dianbin
    Cao, Yan
    Li, Miaomiao
    Meng, Xiangjiao
    AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH, 2017, 9 (03): : 1392 - 1401
  • [28] Serum circulating cell free DNA as potential diagnostic and prognostic biomarker in non-small cell lung cancer
    Alhanafy, A.
    El Shafei, S.
    Habib, M.
    Abdellatif, R.
    Haggag, M.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (04) : S17 - S18
  • [29] Use of cell free DNA as a prognostic biomarker in non-small cell lung cancer patients with bone metastasis
    Ye, Yongjian
    Luo, Zhihang
    Shi, Dejun
    INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS, 2019, 34 (04): : 381 - 388
  • [30] Detection of Promoter DNA Methylation in Urine and Plasma Aids the Detection of Non-Small Cell Lung Cancer
    Liu, Bin
    Filho, Julio Ricarte
    Mallisetty, Apurva
    Villani, Cassandra
    Kottorou, Anastasia
    Rodgers, Kristen
    Chen, Chen
    Ito, Tomoaki
    Holmes, Kyla
    Gastala, Nicole
    Valyi-Nagy, Klara
    David, Odile
    Gaba, Ron C.
    Ascoli, Christian
    Pasquinelli, Mary
    Feldman, Lawrence E.
    Massad, Malek G.
    Wang, Tza-Huei
    Jusue-Torres, Ignacio
    Benedetti, Enrico
    Winn, Robert A.
    Brock, Malcolm V.
    Herman, James G.
    Hulbert, Alicia
    CLINICAL CANCER RESEARCH, 2020, 26 (16) : 4339 - 4348